DESCRIPTION
The laboratory has identified a new protein biomarker, highly specific for breast and colon cancer, which helps predicting the risk for the cancer to relapse and/or to develop metastases.
The analysis of this marker expression by TMA (Tissue MicroArrays) immunohistochemistry on breast and colon cancer samples, has demonstrated that colorectal tumors showing more than 50% positively-stained cells or breast tumors showing less than 50% positively-stained cells are related to high risks of relapse, either local or metastatic.
STAGE OF DEVELOPMENT
Analysis of TMA breast & colorectal cancer samples with RT-QPCR and immunohistochemistry (cancer samples considered of good prognosis using classical markers – Gleason 1 to 4 for colon cancer and SBR 1 to 3 for breast cancer
INTELLECTUAL PROPERTY
Patent pending in EP
Priority date: October, 3rd, 2011 (FR1158910)
ADVANTAGES / NOVELTY
The addition of a single protein marker to predict metastatic progression of good prognosis cancers is:
• Simpler & faster to perform
• Less expensive
APPLICATIONS
• Breast & colorectal cancer prognosis
• Cancer clinical therapeutic decision
COLLABORATION TYPE
PULSALYS looks for industrial partners and offers to grant patent license.
CONTACT
Daphne THOMAS
Tech Transfer Officer - Health
Tél. : +33 (0) 4 26 23 56 78
daphne.thomas@pulsalys.fr